Ignite Creation Date:
2025-12-24 @ 3:28 PM
Ignite Modification Date:
2025-12-26 @ 10:21 PM
Study NCT ID:
NCT03964792
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-01-09
First Post:
2019-05-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE)
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-11-12
Start Date Type:
ACTUAL
Primary Completion Date:
2022-07-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-01
Completion Date Type:
ESTIMATED
First Submit Date:
2019-05-14
First Submit QC Date:
None
Study First Post Date:
2019-05-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-01-08
Last Update Post Date:
2024-01-09
Last Update Post Date Type:
ACTUAL